Mave- tarmbivirkninger generelt forekom hos en større andel af de patienter, der fik ORACEA (13, 4%) end hos placebopatienterne (8, 6%).
Gastrointestinal adverse reactions overall occurred in a higher proportion of patients on ORACEA (13.4%) than on placebo (8.6%).